Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EBITDA (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of EBITDA data on record, last reported at -$4.8 million in Q3 2025.

  • For Q3 2025, EBITDA fell 7.33% year-over-year to -$4.8 million; the TTM value through Sep 2025 reached -$17.6 million, up 17.97%, while the annual FY2024 figure was -$20.4 million, 8.55% up from the prior year.
  • EBITDA reached -$4.8 million in Q3 2025 per GANX's latest filing, up from -$5.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.5 million in Q1 2021 and bottomed at -$8.2 million in Q2 2024.
  • Average EBITDA over 5 years is -$4.7 million, with a median of -$4.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: crashed 560.06% in 2021, then soared 37.8% in 2025.
  • A 5-year view of EBITDA shows it stood at -$3.2 million in 2021, then plummeted by 42.15% to -$4.6 million in 2022, then rose by 3.38% to -$4.4 million in 2023, then rose by 24.42% to -$3.3 million in 2024, then crashed by 43.67% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$4.8 million in Q3 2025, -$5.1 million in Q2 2025, and -$4.4 million in Q1 2025.